ArticleCurrent microbiology2025
Evaluating Antibacterial Efficacy of Cefiderocol and Cefepime/Taniborbactam Against OXA-48-Like and NDM-Expressing Enterobacterales: An In-Vitro and In-Silico Approach.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
New Delhi metallo-β-lactamase (NDM)-producing enterobacterales infections pose significant challenges due to limited treatment options. Recently, a triple combination of ceftazidime/avibactam and aztreonam has been utilized to combat these infections. However, a four-amino-acid insertion in PBP3 and/or the ampC β-lactamase has been linked to the development of resistance to this triple combination in several recent investigations. To evaluate the effectiveness of cefiderocol and cefepime/tazobactam using both in-vitro and in-silico methods, this study examines current non-duplicate isolates of carbapenem-resistant E. coli (n = 40) and carbapenem-resistant K. pneumoniae (n = 40) derived from blood cultures. The MIC of cefepime/taniborbactam and cefiderocol was ascertained using the micro-broth dilution technique. Additionally, computational analysis was performed using molecular docking with AutoDock tools and dynamic simulation with GROMACS, followed by MM-PBSA analysis for a duration of 50 ns. In MIC assays, cefiderocol and cefepime/taniborbactam showed minimal effectiveness against NDM-producing K. pneumoniae and E. coli that possessed OXA-48-like traits. However, both antibiotics showed strong affinity against OXA-48-like producers. Docking studies varied from -4.3 to -8.1 kcal/mol, indicating a higher binding affinity and stronger hydrogen bond formation in OXA-48-like compared to NDM producers. All complexes exhibited stable conformational states, as indicated by analyses of the RMSD, RMSF, Rg, SASA, and hydrogen bond trajectories. Further evidence supports stable BL/BLI interactions within binding sites, mediated by PCA, FEL, and DCCM, as indicated by the binding free energy. Computational studies confirmed better binding affinity for both OXA-48-like and NDM. However, in-vitro studies demonstrated that cefepime/taniborbactam and cefiderocol represent viable alternative options, specifically for OXA-48-like producers, as their effectiveness is significantly compromised in the presence of NDM.
Indexed as
Identifiers
41137955What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.